AstraZeneca PLC

AZN

65.97 (0.70%) 0.46

204.38(B)

Health Care

Pharmaceuticals

AstraZeneca PLC a biopharmaceutical company focuses on the discovery development manufacture and commercialization of prescription medicines. The company’s marketed products include Tagrisso Imfinzi Lynparza Calquence Enhertu Orpathys Truqap Zoladex Faslodex Farxiga Brilinta Lokelma Roxadustat Andexxa Crestor Seloken Onglyza Bydureon Fasenra Breztri Symbicort Saphnelo Tezspire Pulmicort Bevespi and Daliresp for cardiovascular renal metabolism and oncology. Its marketed products also comprise Vaxzevria Beyfortus Synagis FluMist Soliris Ultomiris Strensiq Koselugo and Kanuma for covid-19 and rare disease. The company serves primary care and specialty care physicians through distributors and local representative offices in the United Kingdom rest of Europe the Americas Asia Africa and Australasia. It has a collaboration agreement with Neurimmune AG to develop and commercialize NI006; BenevolentAI for drug discovery for systemic lupus erythematosus; Lunit for developing AI-Powered Digital Pathology Risk Assessment Tools for NSCLC; and Absci Corporation for AI-driven drug discovery against an oncology target. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. AstraZeneca PLC was incorporated in 1992 and is headquartered in Cambridge the United Kingdom.

Holdings:

Cost basis:

AstraZeneca PLC (AZN) price target and intrinsic value estimate

AZN's fair price estimate is $48.6

This valuation is based on a fair P/E of 12.3 and EPS estimates of $3.95

Is AZN overvalued or undervalued?

AZN is currently trading at $65.97

AZN is overvalued by 36% using the pevaluation method.

Do you agree with this valuation?

Valuation

PEvaluation

Low $36.5

Median $48.6

High $60.8

Fair P/E

Margin of safety

Analyst valuation

No analyst price estimates.

Strong Buy5

Buy11

Hold4

Sell0

Strong Sell0

Discounted cash-flow

TTM FCFFCF est.Growth FCFTerminal FCF

Discount rate:

10%

Terminal rate:

Growth phase length:

Growth phase rate:

10%

Economic moat: None/narrow

Overview

Market data

Market cap:$204.38(B)

Enterprise value:$229.74(B)

Total Equity:$40.80(B)

Shares outstanding:3.10(B)

Div. yield:2.25%

P/S:3.99

P/E:31.46

P/FCF:21.30

P/B:5.02

EPS:$2.1

FCF per share:$3.1

Dividend per share:$1.5

Income (TTM)

Revenue$51.21(B)

Gross profit$42.30(B)

EBITDA$18.39(B)

Net income$6.50(B)

Gross margin82.6%

Net margin12.7%

Balance sheet

Total assets$104.92(B)

Total liabilities$64.12(B)

Cash & Short-term inv.$4.93(B)

Long-term debt$28.92(B)

Debt issued$7.12(B)

Debt repaid$-5.24(B)

Cash flow (TTM)

FCF$9.59(B)

CapEx$-1.74(B)

Dividends paid$-4.63(B)

Stock issued$36.00(M)

Stock repurchased$-81.00(M)

Stock-based comp.$579.00(M)

Future Growth

Revenue

CAGR: 5.8%

FY+1$53.11(B)

FY+2$56.95(B)

FY+3$60.26(B)

FY+4$63.21(B)

FY+5$66.54(B)

Net Income

CAGR: 10.7%

FY+1$12.76(B)

FY+2$14.63(B)

FY+3$16.41(B)

FY+4$17.71(B)

FY+5$19.17(B)

EPS

CAGR: 10.1%

FY+1$4.07

FY+2$4.64

FY+3$5.18

FY+4$5.57

FY+5$5.99

FCF per share

CAGR: 11.8%

FY+1$4.14

FY+2$5.15

FY+3$5.78

FY+4$5.98

FY+5$6.46

Similar Companies

Historical Financials

Showing limited histrical data. Access 10+ years of financials now! Upgrade

YearlyQuarterly

Income

RevenueNet IncomeCOGSGross ProfitTotal OpEx.R&DSG&AOperating IncomeInterest ExpenseInterest IncomePre-tax incomeIncome tax

Cash flow

FCFCFONet IncomeD&AStock-based Comp.CFFStock IssuedStock RepurchasedDebt IssuedDebt RepaidDividend PaidCFIAcquisitionsDivestituresCapital Expenditures

Balance sheet

Total AssetsTotal LiabilitiesCurrent assetsCash and EquivalentsShort-term investmentsInventoriesReceivablesNon-current assetsNet PP&EGoodwillCurrent liabilitiesAccounts payableNon-current liabilitiesLong-Term DebtTotal Equity

Shares outstanding

Shares (Basic)Shares (Diluted)

Per share data

EPS (Basic)EPS (Diluted)FCF/ShareDividend/ShareBook value/Share

Ratios

P/EP/FCFP/BP/SEV/EarningsEV/FCFDebt/EquityPayout ratio

Margins

Net Income MarginOperating MarginGross MarginEBITDA MarginFCF Margin

Returns

ROICROAROCEROE

Market Cap.